Opportunity Abounds for Celgene (CELG) in Multiple Segments - Cramer
Tweet
Share
E-mail
Jim Cramer
Get Alerts CELG Hot Sheet
Join SI Premium – FREE
Celgene Corp (Nasdaq: CELG) is ticking higher amid positive comments from stock wunderkind Jim Cramer.
Cramer said that tides have shifted in Big Pharma. Names like Bristol-Myers Squibb (NYSE: BMY) used to be at the forefront of innovation, but as patents continue to expire, smaller outfits might be a better bet for investors.
Growth at Celgene is nearly 23 percent per year, Cramer noted. Despite a recent surge, the stock is still going for just 16 times expected earnings, or 8.6 times FY15 earnings expectations.
But, what makes Celgene so good?
Cramer made three points: first, Celgene has a winner in its blood cancer treatment Revlimid. New indications for the drug might turn it into a $6 billion business.
Next, Celgene's breast cancer treatments might also have expanded indications, like pancreatic cancer, for instance. There might be $1.5 billion of turnover available here.
Finally, Cramer thinks Celgene has a $3 billion opportunity in its arthritis anti-inflammatory portfolio.
Into the open Tuesday, Celgene is up about 0.8 percent.
Cramer said that tides have shifted in Big Pharma. Names like Bristol-Myers Squibb (NYSE: BMY) used to be at the forefront of innovation, but as patents continue to expire, smaller outfits might be a better bet for investors.
Growth at Celgene is nearly 23 percent per year, Cramer noted. Despite a recent surge, the stock is still going for just 16 times expected earnings, or 8.6 times FY15 earnings expectations.
But, what makes Celgene so good?
Cramer made three points: first, Celgene has a winner in its blood cancer treatment Revlimid. New indications for the drug might turn it into a $6 billion business.
Next, Celgene's breast cancer treatments might also have expanded indications, like pancreatic cancer, for instance. There might be $1.5 billion of turnover available here.
Finally, Cramer thinks Celgene has a $3 billion opportunity in its arthritis anti-inflammatory portfolio.
Into the open Tuesday, Celgene is up about 0.8 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Is the global equity rally broadening? UBS weighs in
- BofA says momentum style supported by earnings revisions
- Envoy Medical (COCH) PT Lowered to $2 at H.C. Wainwright
Create E-mail Alert Related Categories
Insiders' Blog, Trader TalkRelated Entities
Jim Cramer, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
